HeyJaredAllison Gatlin
- Indexed articles, last 90 days
- 5
- Latest publication
- Aug 3, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 6, 2026
Latest articles
Three Noteworthy Biotechs Just Reported Earnings — And Only One Recovered (opens the original)
Read excerpt
Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports. The post Three Noteworthy Biotechs Just Reported Earnings — And Only One Recovered appeared first on Investor's Business Daily.
AstraZeneca Nosedives On A Rumored Megamerger; Is $160 Billion Enough? (opens the original)
Read excerpt
AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb. The post AstraZeneca Nosedives On A Rumored Megamerger; Is $160 Billion Enough? appeared first on Investor's Business Daily.
Edwards, The 'Cleanest Large-Cap Medtech Story,' Reverses After Quarterly Beat (opens the original)
Read excerpt
Edwards Lifesciences stock fell Friday, though the medtech company beat Wall Street's top- and bottom-line expectations. The post Edwards, The 'Cleanest Large-Cap Medtech Story,' Reverses After Quarterly Beat appeared first on Investor's Business Daily.
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles (opens the original)
Read excerpt
Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company. The post Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles appeared first on Investor's Business Daily.
Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development (opens the original)
Read excerpt
Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious swelling disease. The post Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development appeared first on Investor's Business Daily.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.